Table 5 Multifactorial analysis of prognostic factors.

From: Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma

Index

Factor

Regression coefficient

Standard error

χ2

P value

HR

95%CI

Lower limit

Upper limit

OS

 Clinical stage

II + III/IV

0.813

0.374

4.711

0.030

2.254

1.082

4.695

 Number of immunotherapy

 ≤ 6/ ≥ 7 cycles

− 0.984

0.420

5.500

0.019

0.374

0.164

0.851

 Immunotherapy Sequence

Sequential/Concenrent

0.976

0.374

6.798

0.009

2.653

1.274

5.525

 Radiation coverage

All/Partial

1.084

0.376

8.298

0.004

2.957

1.414

6.184

 Mid-treatment ALC

Low/Medium/High

0.837

0.256

10.669

0.001

2.309

1.398

3.816

 Short term efficacy

CR + PR/SD + PD

1.026

0.420

5.977

0.014

2.789

1.226

6.346

PFS

 Clinical stage

II + III/IV

0.759

0.282

7.235

0.007

2.135

1.229

3.711

 Immunotherapy sequence

Sequential/Concenrent

0.717

0.277

6.724

0.010

2.048

1.191

3.522

 Post-treatment ALC

Low/Medium/High

0.648

0.197

10.822

0.001

1.911

1.299

2.811

  1. HR Hazard ratio, OS Overall survival, PFS Progression free survival, ALC Absolute lymphocyte count
Back to article page